Related Experiment Video
Updated: May 15, 2025

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Mitigating Brain MR Imaging Degradation Due to Ferumoxytol Therapy in Patients with Iron Deficiency Anemia
Seunghong Rhee1, An M Tran1, Thomas J O'Neill2
1From the Department of Radiology, Texas Tech University Health Sciences Center El Paso, El Paso, Texas.
Abstract:
Ferumoxytol, an FDA-approved treatment for iron deficiency anemia, is frequently used off-label as an MRI contrast agent. However, its unintended effects on brain MRI after anemia treatment, particularly in SWI and GRE sequences, remain insufficiently addressed. This study evaluates the optimal time interval between therapeutic ferumoxytol administration and brain MRI to minimize such effects. Analyzing 40 patients who underwent MRI within 3 months of ferumoxytol treatment, we found that 68% exhibited enhancement or signal drop on T1-weighted images and 63% showed susceptibility artifacts on SWI/GRE sequences. A 5-6 day interval between ferumoxytol administration and MRI examination is recommended to reduce these effects.
Insights
Ferumoxytol, used for anemia, can affect brain MRI scans. Waiting 5-6 days after treatment before magnetic resonance imaging (MRI) minimizes these unintended enhancement and artifact effects.
Area of Science:
- Radiology
- Neuroradiology
- Iron Metabolism
Background:
- Ferumoxytol is an FDA-approved iron deficiency anemia treatment.
- It is commonly used off-label as a magnetic resonance imaging (MRI) contrast agent.
- Unintended effects on brain MRI post-treatment, especially on susceptibility weighted imaging (SWI) and gradient recalled echo (GRE) sequences, require further investigation.
Purpose of the Study:
- To determine the optimal time interval between ferumoxytol administration and brain MRI.
- To minimize unintended enhancement and signal loss artifacts in MRI following ferumoxytol treatment.
Main Methods:
- Retrospective analysis of 40 patients who received brain MRI within 3 months of ferumoxytol treatment.
- Evaluation of MRI sequences including T1 weighted, SWI, and GRE for enhancement and artifacts.
- Correlation of MRI findings with the time interval since ferumoxytol administration.
Main Results:
- 68% of patients showed enhancement or signal drop on T1 weighted images.
- 63% exhibited susceptibility artifacts on SWI/GRE sequences.
- These effects were observed within 3 months of ferumoxytol administration.
Conclusions:
- A 5-6 day interval between ferumoxytol administration and brain MRI is recommended.
- This interval helps reduce unintended enhancement and susceptibility artifacts.
- Optimizing MRI timing improves diagnostic accuracy after ferumoxytol therapy.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...

